SCHEMBL25265115

SCHEMBL25265115

COc1cccc(O)c1C(=O)C=Cc1ccc(C)cc1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.62
MAOA P21397 2/20 0.62
MAOB P27338 2/20 0.62
CYP3A4 P08684 2/20 0.61
ABCG2 Q9UNQ0 2/20 0.58
NFKB1 P19838 4/20 0.57
NFKB2 Q00653 4/20 0.57
RELA Q04206 4/20 0.57
MAPT P10636 3/20 0.57
SLC5A1 P13866 1/20 0.57
SLC5A2 P31639 1/20 0.57
KMT2A Q03164 2/20 0.56
CXCL12 P48061 2/20 0.56
DPP4 P27487 1/20 0.56
MEN1 O00255 1/20 0.56
KCNA3 P22001 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
TP53 P04637 1/20 0.55
ATM Q13315 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25185038 1.00 AURKA (0.62) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL30383378 1.00 AURKA (0.62) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL15631516 0.91 ABCG2 (0.65) MAOAMAOBCYP3A4ABCG2MAPT
SCHEMBL25193820 0.90 NFKB1 (0.69) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL25201284 0.90 NFKB1 (0.69) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL25191835 0.90 NFKB1 (0.69) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL19182846 0.89 ABCG2 (0.71) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL19182845 0.89 ABCG2 (0.71) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL5082312 0.89 MAPT (0.71) AURKAMAOAMAOBCYP3A4ABCG2
SCHEMBL5082313 0.89 MAPT (0.71) AURKAMAOAMAOBCYP3A4ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B AURKA 2987/4885MAOA 1902/4885MAOB 1004/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 AURKA 3511/4885MAOA 3145/4885MAOB 2435/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 AURKA 3511/4885MAOA 3145/4885MAOB 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.